4528:TYO
Ono Pharmaceutical Co Ltd
2 460,00 JPY
arrow_downward
-1,76%(-44,00) 1D
20 ნოე, 15:30:00 GMT+9 · JPY
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 4528...
Open
2 454 JPY
High
2 508 JPY
Low
2 452 JPY
Mkt. cap
1,23 ტრლ.
Avg. vol.
1,93 მლნ.
Volume
2,30 მლნ.
Dividend
3,25%
Quarterly dividend
20 JPY
Ex-dividend date
30 მარ. 2027
P/E ratio
15,49
52-wk high
2 674 JPY
52-wk low
2 014 JPY
EPS
159 JPY
Shares outstanding
514,12 მლნ.
No. of employees
4 ათ.
Open
2 454 JPY
High
2 508 JPY
Low
2 452 JPY
Mkt. cap
1,23 ტრლ.
Avg. vol.
1,93 მლნ.
Volume
2,30 მლნ.
Dividend
3,25%
Quarterly dividend
20 JPY
Ex-dividend date
30 მარ. 2027
P/E ratio
15,49
52-wk high
2 674 JPY
52-wk low
2 014 JPY
EPS
159 JPY
Shares outstanding
514,12 მლნ.
No. of employees
4 ათ.
News stories
From web sources and news partners
CNBC
·
12 საათის წინ
S&P 500 correction: Five forces behind the market sell-off
Yahoo Finance
·
14 საათის წინ
Chips suffer worst week since 2001 as the Nasdaq nears a bear market
Profile
Ono Pharmaceutical Co., Ltd. is one of the largest pharmaceutical companies in Japan. It is headquartered in Chuo-ku, Osaka, Japan, with its major plants in Higashinari-ku, Osaka, and Fujinomiya, Shizuoka., and its central research institute at Minase, Shimamoto-cho, Mishima District, Osaka.
Ono Pharmaceutical's roots go back to 1717 when Ichibei Ono started his dealer business of pharmaceuticals in Osaka. His business expanded and changed its name a few times, and became Ono Pharmaceutical Industrial Co., Ltd. in 1948.
Ono has been listed in Tokyo Stock Exchange since 1963. Its consolidated earnings in the half year ending in March 2018 were 16 billion Japanese yen.
Nivolumab, the cancer drug based on the research of Prof. Dr. Tasuku Honjo of Kyoto University, who received the Nobel Prize later in 2018, is marketed by both Ono Pharmaceutical and Bristol-Myers Squibb.
In 2024, Harvard University and Ono Pharmaceutical entered into a joint research and drug development agreement. Under it, promising projects to test therapeutic targets will be selected over 5 years under the guidance of Harvard's Office of Technology Development, and ONO will fund the work. Wikipedia
About Ono Pharmaceutical Co Ltd
CEOGyo Sagara | Gyo Sagara
Employees4,21 ათ.
Founded1717
Headquartersოსაკა, Osaka, იაპონია
SectorHealth Care
IndustryPharmaceutical industry
Websiteono-pharma.com